



Review Article

# Risk of type 2 diabetes in metabolically healthy people in different categories of body mass index: an updated network meta-analysis of prospective cohort studies

Somayeh Tajik<sup>1</sup>, Atieh Mirzababaei<sup>1,2\*</sup>, Ehsan Ghaedi<sup>3</sup>, Hamed Kord-Varkaneh<sup>4\*</sup>, Khadijeh Mirzaei<sup>1</sup>

<sup>1</sup>Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran

<sup>2</sup>Student's Scientific Research Center, Tehran, Iran

<sup>3</sup>Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

<sup>4</sup>Student Research Committee, Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

## Article info

### Article History:

Received: 7 January 2019  
Accepted: 5 October 2019  
published: 24 October 2019

### Keywords:

BMI  
Obesity  
Metabolic Healthy  
Metabolic Unhealthy  
Metabolic Syndrome  
Diabetes Mellitus Type 2  
T2DM

## Abstract

**Introduction:** Risk of diabetes mellitus type 2 (T2DM) is variable between individuals due to different metabolic phenotypes. In present network meta-analysis, we aimed to evaluate the risk of T2DM related with current definitions of metabolic health in different body mass index (BMI) categories.

**Methods:** Relevant articles were collected by systematically searching PubMed and Scopus databases up to 20 March 2018 and for analyses we used a random-effects model. Nineteen prospective cohort studies were included in the analyses and metabolically healthy normal weight (MHNW) was considered as the reference group in direct comparison for calculating indirect comparisons in difference type of BMI categories.

**Results:** Total of 199403 participants and 10388 cases from 19 cohort studies, were included in our network meta-analysis. Metabolically unhealthy obesity (MUHO) group poses highest risk for T2DM development with 10 times higher risk when is compared with MHNW (10.46 95% CI; 8.30, 13.18) and after that Metabolically unhealthy overweight (MUOW) individuals were at highest risk of T2DM with 7 times higher risk comparing with MHNW (7.25, 95% CI; 5.49, 9.57). Metabolically healthy overweight and obese (MHOW/MHO) individuals have (1.77, 95% CI; 1.33, 2.35) and (3.00, 95% CI; 2.33, 3.85) risk ratio for T2DM development in comparison with MHNW respectively.

**Conclusion:** In conclusion we found that being classified as overweight and obese increased the risk of T2DM in comparison with normal weight. In addition, metabolically unhealthy (MUH) individuals are at higher risk of T2DM in all categories of BMI compared with metabolically healthy individuals.

**Please cite this article as:** Tajik S, Mirzababaei A, Ghaedi E, Kord-Varkaneh H, Mirzaei K. Risk of type 2 diabetes in metabolically healthy people in different categories of body mass index: an updated network meta-analysis of prospective cohort studies. *J Cardiovasc Thorac Res* 2019;11(4):254-263. doi: 10.15171/jcvtr.2019.43.

## Introduction

The prevalence of diabetes has been increasing, and it is been rising among overweight and obese people.<sup>1</sup> Obesity is a risk factor for developing diabetes, postulated by mediation with pathways related with fat tissue metabolism include abnormal beta cell dysfunction and aggravated insulin resistance (IR).<sup>2</sup> Metabolically healthy obese (MHO) is the one of subcategories of obesity without lipid disorders, IR or hypertension.<sup>3</sup> Generally, there is no evidence that these individuals are permanently protected from the risk of obesity-related co-morbidities.<sup>4</sup> Several prospective cohort studies have shown the combined effect of a higher body mass index (BMI) and

metabolic abnormalities in the development of diabetes. Some of these have reported that MHO individuals are not at increased risk for diabetes mellitus type 2 (T2DM) in comparison with metabolically healthy non-obese subjects<sup>5-7</sup> and might not benefit from lifestyle interventions. In return, some articles have provided evidences that MHO phenotype might be associated with a significant increased risk of the development of diabetes in comparison with metabolically healthy non-obese subjects.<sup>8-12</sup> This controversy in these studies may originate from diverse of ethnicity in different populations.<sup>13</sup> and effect of ethnicity on lean body mass.

These data suggested that further studies are required to

\*Corresponding Author: Atieh Mirzababaei, Email: ati\_babae@yahoo.com; Hamed Kord Varkaneh, Email: hamedkord39@yahoo.com

© 2019 The Author (s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

evaluate the risk of diabetes according to the phenotypes of obesity. Two meta-analyses up to 2014<sup>14,15</sup> suggested that MHO phenotype might be associated with a significant increased risk of diabetes development in comparison with metabolically healthy non-obese subjects, while after these meta-analyses several studies have been published.<sup>7,12,16,17</sup> Therefore, this network meta-analysis updated studies up to March 20, 2018 based on ethnicity in different population, and aimed to provide more clear evidence on the risk of diabetes development based on phenotypes of obesity.

## Methods

This network meta-analysis according to the meta-analysis of observational studies in epidemiology (MOOSE) guidelines.<sup>18</sup>

### Search strategy

All relevant published cohort studies that tested the associations of different phenotypes of BMI with risk of T2DM were searched. These studies systematically searched throughout PubMed and Scopus databases up to March 20, 2018 and it was conducted by using MESH and non-MESH keywords and did not use date and language restrictions. The terms were used in the electronic search included “Adiposity”[Mesh]) OR “Adiposity”[Title/Abstract] OR [“Obesity”[Mesh] OR “Obesity”[Title/Abstract] OR “Body Mass Index”[Mesh] OR “Body Mass Index”[Title/Abstract]) OR “BMI” OR “Overweight”[Mesh] OR “Overweight”[Title/Abstract] OR (“Obesity, Metabolically Benign”[Mesh]) OR “benign obesity”[Title/Abstract] OR “healthy obesity”[Title/Abstract]) OR “metabolically healthy obesity”[Title/Abstract]) OR “metabolically benign obesity”[Title/Abstract]) OR (“obesity”[Title/Abstract]) AND “metabolically healthy”[Title/Abstract]) OR (“obesity”[Title/Abstract]) AND “metabolically benign”[Title/Abstract]) AND (“Diabetes Mellitus”[Mesh]) OR “Diabetes Mellitus”[Title/Abstract]) OR “Diabetes Mellitus, Type 2”[Mesh]) OR “Diabetes Mellitus Type 2”[Title/Abstract]) OR “Diabetes Mellitus Type II”[Title/Abstract]) OR “T2DM”[Title/Abstract]) OR “T2D”[Title/Abstract]) OR “type 2 diabetes”[Title/Abstract]) OR “type 2 diabetes mellitus”[Title/Abstract]) OR “Type II diabetes mellitus”[Title/Abstract]) OR “Type II diabetes”[Title/Abstract]) OR Diabet\*[Title/Abstract]) OR “Noninsulin-dependent diabetes mellitus”[Title/Abstract]. In addition, the reference list of obtained articles was manually reviewed.

### Eligible criteria

Articles were considered as qualified for this network meta-analysis if they met the following criteria: had prospective cohort design; tested association of metabolically healthy (MH) or metabolically unhealthy (MUH) phenotypes of BMI with risk of T2DM; reported hazard ratios (HRs), odds ratios (ORs) or relative risks (RRs) for risk of T2DM;

stratified subjects according to weight categories; describes criteria used for defining individuals as MH or MUH and included healthy subjects over 18 years. Studies were excluded if they have following criteria; case reports, cross sectional, literature reviews, animal studies, republished data and grey literature including; congress abstracts, dissertations, and patents. We did not find grey literature in references and related articles. The information could not be extracted were; non-English studies and those which did not report risk of T2DM.

### Study selection

Titles and abstracts of all collected papers were reviewed separately by 2 reviewers (AM and KH-M). Studies that did not meet the eligibility criteria were excluded by using a screening form with a hierarchical approach based on population, study design, or exposure and outcome. Then, full articles of eligible studies were entered to a second evaluation by the same reviewers. Both of reviewers agreed this screening.

### Data extraction

Two reviewers (AM and KH-M) separately extracted data from the included publications. The information acquired from each study includes: authors' name, publication year, country of participants, ethnicity, mean range of age, study sample size, criterion used to define weight of participants, number of participants/ cases in each category, follow-up duration, definition of metabolic phenotypes healthy / unhealthy, confounding factors that were adjusted for in the multivariable analysis, and the HRs/RRs/ORs with corresponding 95% confidence intervals (CI).

### Quality assessment for individual studies

Two assessors (AM and Kh-M) valued the quality of each selected study using the Newcastle-Ottawa scale (NOS) for cohort studies.<sup>19</sup> Studies with a score of 3 to 7 as moderate quality and those with a score of seven or higher were reflected as high quality.

### Statistical analysis

The present network meta-analysis was performed by using pairwise and network commends in Stata (version 14).<sup>20</sup> A random-effects model was conducted to calculate direct and indirect comparisons. The metabolically healthy normal weight (MHNW) was considered as the reference group in direct comparison for obtained indirect comparisons in difference type of BMI categories. Pooled (RRs and 95% CI were calculated using random-effects. The if plot command was employed to produce the inconsistency plot assuming loop-specific heterogeneity estimate and demonstration the exp (IF).<sup>22</sup> Differences in effect estimates between direct and indirect comparisons (statistical inconsistency) in the data was evaluate with local and global methods.<sup>23</sup> Moreover, we conducted subgroup analysis based on different population to better

clarify the risk of diabetes incidence on BMI categories.

## Results

### Study screening

The flowchart of article selection is shown in Figure 1, 650 references were identified through electronic searches and 6 by manual searches, of which 311 were duplicates and 160 were non-relevant, which were excluded on the initial screening of titles and abstracts. Of the remaining, another 166 articles were excluded (detailed reasons for the exclusions are given in Figure 1). Finally, 19 studies involving a total of 199403 participants and 10388 cases were included in our meta-analysis (see Supplementary file 1, Table S1).

### Study characteristics

Nineteen studies reported the risk of T2DM diseases in 199403 participants and 10388 cases. These studies were published between May 30 2006 and 25 June 2017. The age of individuals was 18 to 50 years old. Among the included studies, eleven were from the Asian populations<sup>10,12,16,17,24-30</sup> two from American populations,<sup>5,9</sup> three from European populations<sup>8,11,31</sup> and one, was from Australia populations.<sup>6</sup> Subjects were then classified according to their BMI as normal weight, overweight and obese, only in study of Luo et al,<sup>17</sup> body fat percentage (BF %) >25 % for men or BF (%) >35% for women were defined as being obese.

The duration of follow-up differs from 2 to 20 years. Three studies were conducted on male.<sup>8,16,28</sup> The results in the most of the studies were adjusted for potential confounders, including sex, age, smoking status and physical activity. All studies were cohort. Furthermore, the reference category was a MHNW phenotype in all studies. Table S1 summarizes the characteristics of the included studies. The definition of MH/MUH phenotypes was based on criteria by the Adult Treatment Panel III (ATPIII),<sup>5,9,12,28,30,31</sup> International Diabetes Federation (IDF),<sup>6,26,27</sup> joint committee for developing Chinese guidelines (JCDCG),<sup>17</sup> components metabolic syndrome (MetS),<sup>11</sup> modify ATPIII,<sup>8</sup> Harmonized metabolic syndrome,<sup>10,24</sup> modify (American Heart Association) AHA,<sup>25</sup> Wildman<sup>16,29</sup> and Homeostatic model assessment –insulin resistance (HOMA-IR).<sup>9</sup> In quality assessment of articles two studies received 10 score<sup>27,31</sup> and all other studies received 8 to 9 score.<sup>5,6,8-12,16,17,24-26,28-30</sup>

### BMI and risk of T2DM

Figure 2 shows the network diagrams of direct comparison for different BMI status, with the number of studies reflected by the size of the ages, and the number of patients reflected by the size of the nodes. Six comparisons among BMI groups were considered in our NMA; MHNW was the most “common comparator”. The highest number of comparisons included MHNW compared with MHO





Figure 1. PRISMA flowchart of the study.



**Figure 2.** Network of comparisons included in the analyses. MHNW, metabolically healthy normal weight; MHO, metabolically healthy obesity; MUHO, metabolically unhealthy obesity; MHOW, metabolically healthy overweight; MUHOW, metabolically unhealthy overweight; MUHNW, metabolically unhealthy normal weight.

(n=16), MHO compared with metabolically unhealthy obesity (MUHO) (n=16), MHNW weight compared with metabolically unhealthy normal weight (MUHNW) (n=15), MHO compared with MUHNW (n=15), and MUHNW compared with metabolically unhealthy obesity (MUHO) (n=15), for observe more information see contribute Figure 3.

Nineteen articles were included with 158,583 participants and 7675 diabetes events. The pooled estimates of NMA combining direct and indirect evidence the BMI on risk of T2DM are presented in Table 1 and Figure 4 (Interval plot). The overall results of risk of T2DM were significantly increased in MUHO (RR: 10.46; 95% CI: (8.30-13.18), metabolically unhealthy overweight (MUHOW) (RR: 7.25; 95% CI: (5.49-9.57), MUHNW (RR: 4.30; 95% CI: (3.36-5.50), MHO (RR: 3.00; 95% CI: 2.33-3.85),

metabolically healthy overweight (MHOW) (RR: 1.77; 95% CI: 1.33-2.35) compared with MHNW.

**Subgroups analysis based on ethnicity**

In the subgroups analysis the overall results of risk of T2DM were stronger based on ethnicity, in which risk of T2DM was stronger in MUHO than MUHOW, MUHNW, MHO, MHOW and MHNW, respectively (Tables S2- S4).

**Network inconsistency**

Two approaches were conducted to assess the inconsistency in the NMA. By using a loop-specific approach, each IF (ratio of odds ratios) had a 95% CI, indicating little evidence of loop inconsistency between direct and indirect evidence (Figure S1). The node-splitting approach indicated that no significant inconsistency was observed within the networks (Table S5).

**Publication bias**

Publication bias assessment with funnel plot for the primary outcomes of risk of diabetes in BMI categories did not indicate publication bias in the meta-analysis and was roughly symmetrical (Figure 5).

**Discussion**

Here in present network meta-analysis we aimed to evaluate the risk of T2DM related with current definitions of metabolic health in different BMI categories. The main finding of present study is that being classified as overweight and obese in categories of BMI increased the risk of T2DM in comparison with normal weight. In


		Direct comparisons in the network															
		AvsB	AvsC	AvsD	AvsE	AvsF	BvsC	BvsD	BvsE	BvsF	CvsD	CvsE	CvsF	DvsE	DvsF	EvsF	
Network meta-analysis estimates	Mixed estimates																
		AvsB	26.9	13.7	6.5	13.0	2.2	12.6	5.9	13.8	3.1	0.3	0.4	0.4	0.5	0.4	0.1
		AvsC	14.3	24.5	6.5	11.6	2.2	13.5	0.6	0.3	0.4	9.0	7.0	5.2	2.4	0.5	2.0
		AvsD	12.2	11.7	10.3	12.6	2.4	0.7	6.3	3.8	1.5	9.0	1.3	2.1	15.3	8.5	2.4
		AvsE	13.9	11.9	7.2	19.4	2.5	0.9	1.6	12.1	1.1	3.1	5.7	2.2	11.1	0.8	6.5
		AvsF	11.5	11.0	6.8	11.9	3.9	0.7	2.4	3.8	4.6	3.1	1.3	7.3	2.5	14.7	14.6
		BvsC	11.3	11.6	0.3	0.7	0.1	25.6	6.3	13.0	3.4	9.4	7.4	5.6	2.9	0.1	1.9
		BvsD	9.3	0.9	5.3	2.4	0.7	11.0	11.3	15.2	4.0	9.0	1.0	1.9	16.2	9.1	2.4
		BvsE	10.5	0.2	1.6	8.6	0.6	11.0	7.4	26.2	4.1	3.1	5.8	2.0	11.5	0.4	7.1
		BvsF	8.3	1.2	2.1	2.7	2.4	10.2	6.9	14.4	7.1	3.0	1.1	7.4	3.0	15.0	15.2
		CvsD	0.4	9.5	5.2	3.2	0.6	11.5	6.3	4.4	1.2	17.9	7.7	7.0	14.5	9.7	0.8
		CvsE	0.6	10.7	1.1	8.5	0.4	13.2	1.0	12.1	0.6	11.3	12.0	6.8	13.1	0.3	8.2
		CvsF	0.6	8.4	2.0	3.4	2.4	10.6	2.1	4.4	4.7	10.9	7.3	12.4	0.8	15.7	14.4
		DvsE	0.3	1.4	4.9	6.3	0.3	1.9	6.2	9.2	0.7	8.0	5.0	0.3	32.9	11.9	10.7
		DvsF	0.4	0.4	3.8	0.6	2.4	0.1	4.9	0.5	4.7	7.4	0.2	7.7	16.6	32.5	17.9
	EvsF	0.1	1.7	1.1	5.3	2.5	1.9	1.4	8.1	4.9	0.7	4.5	7.4	15.5	18.7	26.4	
Indirect estimates																	
Entire network		8.0	8.0	4.4	7.4	1.8	8.3	4.7	9.4	3.1	7.1	4.5	5.2	10.2	9.3	8.7	
Included studies		16	9	15	16	9	9	15	16	9	9	9	8	15	9	9	

**Figure 3.** Contribute figure. Note: A: metabolically healthy normal weight, B: metabolically healthy obesity, C: metabolically healthy overweight, D: metabolically unhealthy normal weight, E: metabolically unhealthy obesity, F: metabolically unhealthy overweight.

**Table 1.** Network estimated relative risk (95% CI) of BMI categories on incidence of diabetes

<u>_MUHOW_</u>	<u>_MUHO_</u>	<u>_MUHWN_</u>	<u>_MHOW_</u>	<u>_MHO_</u>	<u>_MHNW_</u>
MUHOW	1.44 (1.10,1.90)	0.59 (0.44,0.79)	0.24 (0.18,0.33)	0.41 (0.31,0.55)	0.14 (0.10,0.18)
0.69 (0.53,0.91)	MUHO	0.41 (0.32,0.53)	0.17 (0.13,0.22)	0.29 (0.22,0.37)	0.10 (0.08,0.12)
1.69 (1.26,2.25)	2.43 (1.90,3.11)	MUHWN	0.41 (0.31,0.55)	0.70 (0.54,0.91)	0.23 (0.18,0.30)
4.09 (3.01,5.56)	5.90 (4.45,7.82)	2.43 (1.80,3.26)	MHOW	1.69 (1.25,2.28)	0.56 (0.42,0.75)
2.42 (1.80,3.24)	3.49 (2.72,4.47)	1.44 (1.10,1.87)	0.59 (0.44,0.80)	MHO	0.33 (0.26,0.43)
7.25 (5.49,9.57)	10.46 (8.30,13.18)	4.30 (3.36,5.50)	1.77 (1.33,2.35)	3.00 (2.33,3.85)	MHNW

MHNW, metabolically healthy normal weight; MHO,metabolically healthy obesity; MUHO,metabolically unhealthy obesity; MHOW,metabolically healthy overweight; MUHOW,metabolically unhealthy overweight; MUHWN,metabolically unhealthy normal weight




**Figure 4.** Interval plot. MHNW, metabolically healthy normal weight; MHO, metabolically healthy obesity; MUHO, metabolically unhealthy obesity; MHOW, metabolically healthy overweight; MUHOW, metabolically unhealthy overweight; MUHWN, metabolically unhealthy normal weight.

addition MUH individuals are at higher risk of T2DM in all categories of BMI compared with MH individuals. In fact all groups within BMI and MH categories had higher risk when compared with MHNW group. MUHO group demonstrates the highest risk for T2DM development when compared with MHNW with 10 times higher (10.46 95% CI; 8.30, 13.18) and after that MUOW individuals were at highest risk of T2DM with 7 times higher risk when compared with MHNW. Metabolically healthy overweight and obese individuals has (1.77, 95% CI; 1.33, 2.35) and (3.00, 95% CI; 2.33, 3.85) risk ratio for T2DM development in comparison with MHNW respectively. Also MUHWN individuals has higher risk (4.30, 95% CI; 3.36, 5.50) in comparison with MHNW subjects. The 4 times higher risk of MUHWN compared with MHNW subjects (4.30, 95% CI; 3.36, 5.50) was also higher than MHOW and MHO risk of T2DM development in comparison with MHNW individuals. Eventually MUHO (3.49, 95% CI; 2.72,4.47) and MUHOW individuals (4.09, 95% CI; 3.01,5.56) although has higher risk for T2DM development compared with same BMI categories including MHO and MHOW respectively, but the risk

was definitely lower than what is obtained for MUHWN compared with MHNW individuals which must be considered in future studies.

Although MHO group had 3 times higher risk of T2DM compared with MHNW as reported previously, their risk also were lower significantly with 10 times higher risk



**Figure 5.** Comparison-adjusted funnel plot of publication bias in relations of diabetes incidence in BMI categories.

in MUO group. Interestingly these findings highlight the effect of metabolic health status of individuals for predicting T2DM development in populations; metabolic abnormalities may be more contribute to the development of T2DM rather than exclusive anthropometric measurement like BMI. Here we showed increased risk of T2DM development in MHO individuals which is consistent with some,<sup>32-37</sup> but not all previous studies.<sup>6, 38-41</sup> In fact BMI could be a risk factor for T2DM regardless of the metabolic status of the participants. In a meta-analysis MHO individuals had an increased risk of develop diabetes compared with MHNW individuals.<sup>42</sup> However both the Framingham<sup>38</sup> and an Australian cohort study<sup>6</sup> reported that MHO and MHNW individuals had similar risk of developing diabetes during 11-year period.

Obesity might not be diabetogenic per se, and not all MH individuals with obesity are at the same risk of diabetes onset. Adipose tissue as an endocrine organ produces different adipocytokines like leptin and adiponectin, which could be causally associated with wide range of metabolic diseases.<sup>43</sup> On the other hand, abundance adipose tissue can increase inflammatory status and oxidative stress by secreting markers like CRP, interleukin-6, monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), all of which have been suggested to be contributed in the pathogenesis of diabetes.<sup>44</sup> In addition due to excess of adipose tissue accumulation pancreatic fat, may contribute to  $\beta$ -cell dysfunction and probably to the following development of T2DM.<sup>45,46</sup> However, it has been suggested that the MHO phenotype is transient and ultimately progresses to overt metabolic abnormalities in significant percentage of individuals over time.<sup>47</sup> Thus additional mechanistic studies are required to clarify the relationship between the MHO phenotype and the impact of changes in obese phenotype overtime and the increased risk of diabetes.

We showed that MUHNW individuals have higher risk for T2DM development. Actually MUHNW subjects represent another spectrum of obesity.<sup>48</sup> These individuals show more adiposity, more abdominal fat distribution, and dyslipidemia than MHNW individuals.<sup>49</sup> It has been proposed that disturbance in fat storage in adipose tissue could elucidate the increase in triglyceride levels and the ectopic fat deposition in the liver and muscle.<sup>50</sup> Furthermore MUHNW individuals have decreased compensatory insulin response in comparison with MHNW individuals.<sup>51</sup> Previous studies indicate that MUHNW individuals are at increased risk of T2DM, cardiovascular diseases and mortality<sup>52-54</sup> which is aligned with our data in terms of the risk of developing T2DM.

The definitions of overweight and obesity are according to information from European populations.<sup>55</sup> Ethnic differences in the prevalence of T2DM reported in several countries. Higher T2DM prevalence in Asia and Africa and their descendants reported in comparison with whites.<sup>56</sup> Asian individuals are more expected to have

a higher percentage of fat or visceral adipose tissue at a given BMI than Europeans.<sup>57</sup> So that the associations of BMI and health outcomes may differ between Asian and European populations.<sup>58</sup> Asians have shown to have an increased risk of T2DM in a comparatively low BMI.<sup>58</sup> Our results indicated that the risk for developing T2DM in increased BMI categories defined by lower cutoff points for Asians were to some extent higher than those obtained using BMI criteria for European populations but lower than American population. However, in metabolically unhealthy groups these ratios changed totally with a considerable higher risk in American population (18 times higher risk (18.76, 95% CI: 12.62, 27.89) but approximately same risk between European and Asian population (about 10 times higher). The ethnic dissimilarity may associate to the genetic factors, lifestyle factors or body composition. Obesity reported with different incidence all over the world from Asia to America and Europe which can affect T2DM development. However, several studies showed significant differences regarding insulin resistance and hyperinsulinemia independent of obesity in different ethnics like non-Hispanic, Asian American and native Americans,<sup>59</sup> Differences in brown adipose tissue in South Asians may contributed to an reduced energy expenditure and T2DM.<sup>56</sup> BF (%) in Indian individuals is higher than that in European at a given BMI; this 'thin-fat' phenotype is associated with higher insulin resistance. Recently Indian people with T2DM reported to have lower beta cell function compared with Europeans which is originates during intrauterine development, and not only diet; this fact support the 'thrifty phenotype' hypothesis.<sup>60</sup> Diet may also play a fundamental role in intergenerational vulnerability to T2DM. Maternal vitamin B12 deficiency and hyperhomocysteinemia are related to IR and adiposity in childhood.<sup>61</sup> Macronutrient imbalances and higher glycemic index affect IR.<sup>62</sup> Different sphingolipid, plasma amino acid especially branched-chain amino acids, and mono- and polyunsaturated acylcarnitine and plasma levels reported in different races. Differences in these metabolites were associated with cumulative and incident T2DM.<sup>56</sup> Genetic background also has been proposed as a possible description for ethnic differences in DM risk; as more than 40 loci are associated with an increased risk for T2DM regardless of race or ethnicity and due to few large-scale genetic studies future finding for genome wide association studies of T2DM is needed. Different HbA1c level also reported in different possibly due to erythrocyte differences.<sup>59</sup> All these factors affect the possible susceptibility for T2DM in different races.

Network meta-analysis allow indirect comparison of evidence, which has previously published.<sup>63</sup> Here, we used the paired-wise method in order to estimate, for each study, the risk of metabolically unhealthy vs healthy individuals in different BMI categories. This method makes comparison of different categories with each other possible which could be considered as one of strength of

present study. However some points must be considered before making any solid conclusion about present findings. Although several studies provided longitudinal data on the risk of developing T2DM in different obesity phenotypes, it is difficult to straightly compare results of studies because no consensus has been achieved yet concerning the best criteria for definition of metabolic health.<sup>40,64</sup> On the other hand definitions used for the diagnosis of diabetes differed among studies.<sup>34,38,65,66</sup> Different definitions allowed only indirect comparisons phenotypes prevalence in different populations which indicated highly inconsistent prevalence among different studies.<sup>67,68</sup> Other possible factor which has not been evaluated in present study is that for example, liver fat content mostly explains different risk rates between MHO and MUHO,<sup>69</sup> in fact presence of non-alcoholic fatty liver disease has led to different risk rate among individuals for T2DM development even in same obesity phenotype.<sup>70</sup> So in future, other possible confounding factors like the degree of inflammation must be considered.<sup>71</sup> At last it must be noted that MHO might be a transient setting<sup>72</sup>; thus, the influence of changes in obese phenotypes on the risk of developing T2DM should be investigated in future studies. The significance to consider for the time-varying nature of these exposures is also reported in meta-analyses, which found elevated risks especially among studies with longer follow-up.<sup>40,73</sup> Duration and degree of obesity are related to become MUHO<sup>74</sup> which could be a reason for the diverse results among previous studies.<sup>40,67,73</sup>

### Conclusion

In conclusion we found that being classified as overweight and obese increased the risk of T2DM in comparison with normal weight. In addition metabolically unhealthy individuals are at higher risk of T2DM in all categories of BMI compared with metabolically healthy individuals. MUHO showed higher risk for T2DM development than MHO and MHNW which shows that metabolic abnormalities might contribute to the development of T2DM more than BMI. Furthermore, MUHNW showed increased risk for T2DM development than MHNW which is also higher than MHO and MHOW. Interestingly, the risk for MUHNW compared with MHNW was also higher than MUHO and MUHOW comparing with MHNW, which must be considered in future studies.

### Competing interests

There was no competing financial interest in relation to current study.

### Ethical approval

Not applicable.

### Supplementary Materials

Supplementary file 1 contains Figure S1 and Tables S1-S5.

### Acknowledgments

This study was supported by the Student's Scientific Research Center, Tehran, Iran.

### References

1. WHO homepage. Available from: <http://www.who.int/>.
2. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *JAMA* 2003;289(1):76-9. doi: 10.1001/jama.289.1.76
3. Roberson LL, Aneni EC, Maziak W, Agatston A, Feldman T, Rouseff M, et al. Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. *BMC Public Health* 2014;14:14. doi: 10.1186/1471-2458-14-14
4. Marini MA, Succurro E, Frontoni S, Hribal ML, Andreozzi F, Lauro R, et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. *Diabetes Care* 2007;30(8):2145-7. doi: 10.2337/dc07-0419
5. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. *J Clin Endocrinol Metab* 2006;91(8):2906-12. doi: 10.1210/jc.2006-0594
6. Appleton SL, Seaborn CJ, Visvanathan R, Hill CL, Gill TK, Taylor AW, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. *Diabetes Care* 2013;36(8):2388-94. doi: 10.2337/dc12-1971
7. Kim NH, Seo JA, Cho H, Seo JH, Yu JH, Yoo HJ, et al. Risk of the Development of Diabetes and Cardiovascular Disease in Metabolically Healthy Obese People: The Korean Genome and Epidemiology Study. *Medicine (Baltimore)* 2016;95(15):e3384. doi: 10.1097/md.0000000000003384
8. Arnlov J, Sundstrom J, Ingelsson E, Lind L. Impact of BMI and the metabolic syndrome on the risk of diabetes in middle-aged men. *Diabetes Care* 2011;34(1):61-5. doi: 10.2337/dc10-0955
9. Aung K, Lorenzo C, Hinojosa MA, Haffner SM. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. *J Clin Endocrinol Metab* 2014;99(2):462-8. doi: 10.1210/jc.2013-2832
10. Kim CH, Kim HK, Bae SJ, Kim EH, Park JY. Independent impact of body mass index and metabolic syndrome on the risk of type 2 diabetes in Koreans. *Metab Syndr Relat Disord* 2012;10(5):321-5. doi: 10.1089/met.2011.0143
11. Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, Garcia-Fuentes E, Almaraz MC, Colomo N, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. *J Clin Endocrinol Metab* 2013;98(6):2318-25. doi: 10.1210/jc.2012-4253
12. Latifi SM, Karandish M, Shahbazian H, Taha JM, Cheraghian B, Moradi M. Prevalence of Metabolically Healthy Obesity (MHO) and its relation with incidence of metabolic syndrome, hypertension and type 2 Diabetes amongst individuals aged over 20 years in Ahvaz: A 5 Year

- cohort Study (2009-2014). **Diabetes Metab Syndr** 2017;11 Suppl 2:S1037-s40. doi: 10.1016/j.dsx.2017.07.036
13. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). **Arch Intern Med** 2008;168(15):1617-24. doi: 10.1001/archinte.168.15.1617
  14. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. **Obes Rev** 2014;15(6):504-15. doi: 10.1111/obr.12157
  15. Lotta LA, Abbasi A, Sharp SJ, Sahlqvist AS, Waterworth D, Broxnan JM, et al. definitions of metabolic health and risk of future type 2 diabetes in BMI categories: a systematic review and network meta-analysis. **Diabetes Care** 2015;38(11):2177-87. doi: 10.2337/dc15-1218
  16. Ryoo JH, Park SK, Ye S, Choi JM, Oh CM, Kim SY, et al. Estimation of risk for diabetes according to the metabolically healthy status stratified by degree of obesity in Korean men. **Endocrine** 2015;50(3):650-8. doi: 10.1007/s12020-015-0635-5
  17. Luo D, Liu F, Li X, Yin D, Lin Z, Liu H, et al. Comparison of the effect of 'metabolically healthy but obese' and 'metabolically abnormal but not obese' phenotypes on development of diabetes and cardiovascular disease in Chinese. **Endocrine** 2015;49(1):130-8. doi: 10.1007/s12020-014-0444-2
  18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. **JAMA** 2000;283(15):2008-12. doi: 10.1001/jama.283.15.2008
  19. Wells G, editor SBOD. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of non-randomised Studies in Meta-analysis. Proceedings of the Third Symposium on Systematic Reviews beyond the Basics; 2000.
  20. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. **PLoS One** 2013;8(10):e76654. doi: 10.1371/journal.pone.0076654
  21. White IR. Network meta-analysis. **Stata J** 2015;15(4):951-85
  22. Dias S, Welton N, Caldwell D, Ades A. Checking consistency in mixed treatment comparison meta-analysis. **Stat Med** 2010;29(7-8):932-44. doi: 10.1002/sim.3767
  23. Song F, Clark A, Bachmann MO, Maas J. Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons. **BMC Med Res Methodol** 2012;12(1):138. doi: 10.1186/1471-2288-12-138
  24. Hadaegh F, Bozorgmanesh M, Safarkhani M, Khalili D, Azizi F. Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome? **BMC Public Health** 2011;11:383. doi: 10.1186/1471-2458-11-383
  25. Hwang LC, Bai CH, Sun CA, Chen CJ. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. **Asia Pac J Clin Nutr** 2012;21(2):227-33.
  26. Heianza Y, Kato K, Kodama S, Suzuki A, Tanaka S, Hanyu O, et al. Stability and changes in metabolically healthy overweight or obesity and risk of future diabetes: Niigata wellness study. **Obesity** 2014;22(11):2420-5. doi: 10.1002/oby.20855
  27. Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, et al. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). **J Clin Endocrinol Metab** 2014;99(8):2952-60. doi: 10.1210/jc.2013-4427
  28. Twig G, Afek A, Derazne E, Tzur D, Cukierman-Yaffe T, Gerstein HC, et al. Diabetes risk among overweight and obese metabolically healthy young adults. **Diabetes Care** 2014;37(11):2989-95. doi: 10.2337/dc14-0869
  29. Rhee EJ, Lee MK, Kim JD, Jeon WS, Bae JC, Park SE, et al. Metabolic health is a more important determinant for diabetes development than simple obesity: a 4-year retrospective longitudinal study. **PLoS One** 2014;9(5):e98369. doi: 10.1371/journal.pone.0098369
  30. Jung CH, Lee MJ, Kang YM, Jang JE, Leem J, Hwang JY, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. **J Clin Endocrinol Metab** 2015;100(3):934-41. doi: 10.1210/jc.2014-3885
  31. Hinnouho GM, Czernichow S, Dugravot A, Nabi H, Brunner EJ, Kivimaki M, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. **Eur Heart J** 2015;36(9):551-9. doi: 10.1093/eurheartj/ehu123
  32. Hinnouho G-M, Czernichow S, Dugravot A, Batty GD, Kivimaki M, Singh-Manoux A. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? **Diabetes Care**. 2013;36(8):2294-300. doi: 10.2337/dc12-1654
  33. Hinnouho G-M, Czernichow S, Dugravot A, Nabi H, Brunner EJ, Kivimaki M, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. **Eur Heart J** 2014;36(9):551-9. doi: 10.1093/eurheartj/ehu123
  34. Johan Årnlöv MD P, Johan Sundström MD P, Erik Ingelsson MD P, Lars Lind MD P. Impact of BMI and the Metabolic Syndrome on the Risk of Diabetes in Middle-Aged Men. **Diabetes Care** 2011;34(1):61. doi: 10.2337/dc10-0955
  35. Årnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. **Circulation** 2010;121(2):230-6. doi: 10.1161/CIRCULATIONAHA.109.887521
  36. Blüher M. Mechanisms in endocrinology: Are metabolically healthy obese individuals really healthy? **Eur J Endocrinol** 2014;EJE-14-0540. doi: 10.1530/EJE-14-0540
  37. Jung CH, Lee MJ, Kang YM, Jang JE, Leem J, Hwang JY, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. **J Clin Endocrinol Metab** 2015;100(3):934-41. doi: 10.1210/jc.2014-3885
  38. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. **J Clin Endocrinol Metab** 2006;91(8):2906-12. doi: 10.1210/jc.2006-0594



39. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragnoli F, Villa M, et al. Prevalence, metabolic features and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. **Diabetes Care** 2010. doi: 10.2337/dc10-0665
40. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. **Ann Intern Med** 2013;159(11):758-69. doi: 10.7326/0003-4819-159-11-201312030-00008
41. Blüher M. Are there still healthy obese patients? Current Opinion in Endocrinology, Diabetes and Obesity. **Curr Opin Endocrinol Diabetes Obes** 2012;19(5):341-6. doi: 10.1097/MED.0b013e328357f0a3
42. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. **Obes Rev** 2014;15(6):504-15. doi: 10.1111/obr.12157
43. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. **Clin Endocrinol (Oxf)** 2006;64(4):355-65. doi: 10.1111/j.1365-2265.2006.02474.x
44. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. **Trends Immunol** 2004;25(1):4-7. doi: 10.1016/j.it.2003.10.013
45. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, Van Waesberghe JHT, Schindhelm RK, et al. Pancreatic fat content and  $\beta$ -cell function in men with and without type 2 diabetes. **Diabetes Care** 2008;31(5):e38. doi: 10.2337/dc07-0326
46. Gaborit B, Abdesselam I, Kober F, Jacquier A, Ronsin O, Emungania O, et al. Ectopic fat storage in the pancreas using <sup>1</sup>H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. **Int J Obes (Lond)** 2015;39(3):480. doi: 10.1038/ijo.2014.126
47. Chang Y, Ryu S, Suh B, Yun K, Kim C, Cho S. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. **Int J Obes (Lond)** 2012;36(9):1187. doi: 10.1038/ijo.2011.247
48. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. **Diabetes** 1998;47(5):699-713. doi: 10.2337/diabetes.47.5.699
49. Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Murashima S, Maruyama N, et al. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. **Diabetes Care** 2003;26(8):2341-4. doi: 10.2337/diacare.26.8.2341
50. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? **J Clin Endocrinol Metab** 2004;89(6):2569-75. doi: 10.1210/jc.2004-0165
51. Succurro E, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Lauro R, et al. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. **Obesity** 2008;16(8):1881-6. doi: 10.1038/oby.2008.308
52. Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? **Diabetes Care** 2009;32(12):2297-9. doi: 10.2337/dc09-0574
53. Hwang L-C, Bai C-H, Sun C-A, Chen C-J. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. **Asia Pac J Clin Nutr** 2012;21(2):227-33.
54. Kwon B-J, Kim D-W, Her S-H, Kim D-B, Jang S-W, Cho E-J, et al. Metabolically obese status with normal weight is associated with both the prevalence and severity of angiographic coronary artery disease. **Metabolism** 2013;62(7):952-60. doi: 10.1016/j.metabol.2013.01.006
55. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. **N Engl J Med** 2011;364(8):719-29. doi: 10.1056/NEJMoa1010679
56. van Valkengoed IG, Argmann C, Ghauharali-van der Vlugt K, Aerts JM, Brewster LM, Peters R, et al. Ethnic differences in metabolite signatures and type 2 diabetes: a nested case-control analysis among people of South Asian, African and European origin. **Nutr Diabetes** 2017;7(12):300. doi: 10.1038/s41387-017-0003-z
57. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. **Nat Rev Endocrinol** 2012;8(4):228. doi: 10.1038/nrendo.2011.183
58. WHO EC. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. **Lancet** 2004;363(9403):157. doi: 10.1016/S0140-6736(03)15268-3
59. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. **Curr Diab Rep** 2013;13(6):814-23. doi: 10.1007/s11892-013-0421-9
60. Golden SH, Yajnik C, Phatak S, Hanson RL, Knowler WC. Racial/ethnic differences in the burden of type 2 diabetes over the life course: a focus on the USA and India. **Diabetologia** 2019;62(10):1751-1760. doi: 10.1007/s00125-019-4968-0
61. Yajnik C, Deshpande S, Jackson A, Refsum H, Rao S, Fisher D, et al. Vitamin B 12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. **Diabetologia** 2008;51(1):29-38. doi: 10.1007/s00125-007-0793-y
62. Burden M, Samanta A, Spalding D, Burden A. A comparison of the glycaemic and insulinaemic effects of an Asian and a European meal. **Practical Diabetes International** 1994;11(5):208-11. doi: 10.1002/pdi.1960110508
63. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. **Res Synth Methods** 2012;3(2):111-25. doi: 10.1002/jrsm.1045
64. Frühbeck G, Toplak H, Woodward E, Halford JC, Yumuk V. Need for a paradigm shift in adult overweight and obesity management—an EASO position statement on a pressing public health, clinical and scientific challenge in Europe. **Obes Facts** 2014;7(6):408-16. doi: 10.1159/000370038
65. Hadaegh F, Bozorgmanesh M, Safarkhani M, Khalili D, Azizi F. Predictability of body mass index for diabetes: affected by the presence of metabolic syndrome? **BMC Public Health** 2011;11(1):383. doi: 10.1186/1471-2458-11-383
66. Kim C-H, Kim H-K, Bae S-J, Kim E-H, Park J-Y. Independent impact of body mass index and metabolic syndrome on the risk of type 2 diabetes in Koreans. **Metab Syndr Relat Disord** 2012;10(5):321-5. doi: 10.1089/met.2011.0143

67. Stefan N, Häring H-U, Hu FB, Schulze MB. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. **Lancet Diabetes Endocrinol** 2013;1(2):152-62. doi: 10.1016/S2213-8587(13)70062-7
68. Lee SH, Ha HS, Park YJ, Lee JH, Yim HW, Yoon KH, et al. Identifying metabolically obese but normal-weight (MONW) individuals in a nondiabetic Korean population: the Chungju Metabolic disease Cohort (CMC) study. **Clin Endocrinol (Oxf)** 2011;75(4):475-81. doi: 10.1111/j.1365-2265.2011.04085.x
69. Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study. **Lancet Diabetes Endocrinol** 2018;6(9):714-724. doi: 10.1016/S2213-8587(18)30137-2
70. Chang Y, Jung HS, Yun KE, Cho J, Ahn J, Chung EC, et al. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease. **Obesity (Silver Spring)** 2016;24(9):1996-2003. doi: 10.1002/oby.21580
71. Twig G, Afek A, Derazne E, Tzur D, Cukierman-Yaffe T, Gerstein HC, et al. Diabetes risk among overweight and obese metabolically healthy young adults. **Diabetes Care** 2014;37(11):2989-95. doi: 10.2337/dc14-0869
72. Soriguer F, Gutiérrez-Repiso C, Rubio-Martín E, García-Fuentes E, Almaraz MC, Colomo N, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. **J Clin Endocrinol Metab** 2013;98(6):2318-25. doi: 10.1210/jc.2012-4253
73. Eckel N, Meidtner K, Kalle-Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. **Eur J Prev Cardiol** 2016;23(9):956-66. doi: 10.1177/2047487315623884
74. Mongraw-Chaffin M, Foster MC, Kalyani RR, Vaidya D, Burke GL, Woodward M, et al. Obesity severity and duration are associated with incident metabolic syndrome: evidence against metabolically healthy obesity from the multi-ethnic study of atherosclerosis. **J Clin Endocrinol Metab** 2016;101(11):4117-24. doi: 10.1210/jc.2016-2460